RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.28
+0.00 (+0.01%)
As of 2:40PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.28
Open3.26
Bid3.23 x 400
Ask3.30 x 100
Day's Range3.13 - 3.43
52 Week Range2.91 - 11.20
Volume48,717
Avg. Volume194,381
Market Cap7.773M
Beta1.23
PE Ratio (TTM)N/A
EPS (TTM)-8.05
Earnings DateMar 28, 2018 - Apr 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.00
Trade prices are not sourced from all markets
  • PR Newswire17 days ago

    RXi Pharmaceuticals to Present at the BIO CEO and Investor Conference

    MARLBOROUGH, Mass., Feb. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will give a webcast presentation at the BIO CEO and Investor Conference.

  • PR Newswire29 days ago

    RXi Pharmaceuticals Regains Compliance with NASDAQ Listing Requirements

    MARLBOROUGH, Mass., Jan. 24, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing RNAi-based immunotherapies to treat cancer, today announced that it received a notice from the NASDAQ Stock Market that the closing bid price of the Company's common stock has been at $1.00 per share or greater for ten consecutive days.  Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

  • PR Newswirelast month

    RXi Pharmaceuticals to Present at Immuno-Oncology Frontiers World Conference

    MARLBOROUGH, Mass., Jan. 17, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced that it will give an oral presentation highlighting the company's proprietary therapeutic platform at the Immuno-Oncology Frontiers World conference.

  • PR Newswirelast month

    RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth

    "After a thorough review of our business operations, development programs and financial resources, a decision was made to focus our efforts on RXi's expanding and promising immuno-oncology programs to accelerate growth and in turn support a return on investment for our shareholders," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals.  He stated that: "The positive clinical results recently announced from our Phase 2 dermatology study validate the safety and efficacy of our sd-rxRNA therapeutics in humans.

  • ACCESSWIRElast month

    Blog Exposure - RXi Pharma to Execute Reverse Stock Split

    LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free research report on RXi Pharmaceuticals Corp. (NASDAQ: RXII ). If you want access to this report all you need to ...

  • PR Newswire2 months ago

    RXi Pharmaceuticals Announces Reverse Stock Split

    MARLBOROUGH, Mass., Jan. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018, and shares of RXi Pharmaceuticals common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "RXII," at the market open on January 8, 2018. The new CUSIP number for the Company's common stock following the reverse stock split will be 74979C808.  In addition, pursuant to their terms, a proportionate adjustment will be made to the per share exercise prices and number of shares issuable under all of the Company's outstanding stock options and warrants to purchase shares of common stock.

  • PR Newswire2 months ago

    RXi Pharmaceuticals to Present at the 10th Annual Biotech Showcase Conference

    MARLBOROUGH, Mass., Dec. 29, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at the 10th Annual Biotech Showcase™. Taking place during one of the industry's largest annual healthcare investor conferences, this investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.  The conference will be held January 8–10, 2018 at the Hilton San Francisco Union Square, California. Dr. Cauwenbergh will present an overview of the Company's novel self-delivering RNAi (sd-rxRNA®) technology and the multiple business development and commercial opportunities available based on this proprietary platform.

  • GlobeNewswire2 months ago

    Streetwise Reports Examines How 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform

    SAN FRANCISCO, Dec. 21, 2017-- Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology.. Included in this article is: RXi Pharmaceuticals ...

  • PR Newswire2 months ago

    RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring

    - RXI-109 is a self-delivering RNAi (sd-rxRNA) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and plays a key role in tissue regeneration and repair. - Study successfully meets primary effectiveness objective with statistically significant outcomes for improved visual appearance for RXI-109 treated scar over control. MARLBOROUGH, Mass., Dec. 18, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced positive results with its lead clinical compound RXI-109 in a Phase 2 clinical trial.

  • ACCESSWIRE2 months ago

    Wired News – Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells

    Stock Monitor: XTL Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on RXi Pharmaceuticals Corp. (NASDAQ: RXII ), which is readily accessible ...

  • PR Newswire2 months ago

    Medigene Collaborates with RXi Pharmaceuticals to Further Sharpen its Therapeutic T cells

    MARLBOROUGH, Mass., Dec. 11, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) announced today that it has entered into a research collaboration with Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) to explore potential synergies of using RXi's self-delivering RNAi technology (sd-rxRNA®) in combination with Medigene's recombinant TCRs to develop modified T cells with enhanced efficacy and/or safety. The preclinical research program will examine the applicability of RXi's sd-rxRNA technology to be integrated into Medigene's process to produce receptor-modified T cells with the ultimate goal to further improve Medigene's T cell therapies for the treatment of cancer patients.

  • Zacks Small Cap Research3 months ago

    RXII: sd-rxRNA: A Flexible Platform for Oncology

    NASDAQ:RXII Immunotherapy is one of the most exciting areas in biotechnology today.  It holds the promise of improved efficacy and greater safety by augmenting and enhancing the body’s innate ability to ...

  • PR Newswire3 months ago

    RXi Pharmaceuticals and the Center for Cancer Immune Therapy at Herlev Hospital Announce Research Collaboration

    MARLBOROUGH, Mass., Dec. 1, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics and the Center for Cancer Immune Therapy (CCIT) at Herlev Hospital, a leading European center for use of tumor infiltrating lymphocytes (TIL) for adoptive T-cell therapy (ACT), today announced that they have entered into a collaborative research agreement to evaluate the potential of RXi's novel self-delivering RNAi (sd-rxRNA®) technology platform in TILs for the use in treatment for a number of cancer types, including melanoma and ovarian cancer.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing Program

    MARLBOROUGH, Mass., Nov. 29, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today the results of a consumer/functional testing program with RXI-231, a cosmetic ingredient based on sd-rxRNA® that targets tyrosinase (TYR). The cosmetic product is a gel formulation designed to aid in the reduction of pigmentation and thereby improving skin appearance. The results from the completed consumer testing program, in combination with previously announced preclinical data on melanin content in cultured melanocytes and 3-dimensional reconstituted human skin models, show that RXI-231 has the potential to reduce skin pigmentation induced by UV exposure in vivo.

  • What Are The Drivers Of RXi Pharmaceuticals Corporation’s (RXII) Risks?
    Simply Wall St.3 months ago

    What Are The Drivers Of RXi Pharmaceuticals Corporation’s (RXII) Risks?

    If you are a shareholder in RXi Pharmaceuticals Corporation’s (NASDAQ:RXII), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • ACCESSWIRE3 months ago

    Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre

    Research Desk Line-up: Jazz Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for RXi ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of RXII earnings conference call or presentation 8-Nov-17 9:30pm GMT

    Q3 2017 Rxi Pharmaceuticals Corp Earnings Call

  • PR Newswire3 months ago

    RXi Pharmaceuticals and Gustave Roussy Announce Research Collaboration

    MARLBOROUGH, Mass., Nov. 13, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics, and Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced that they have entered into a collaborative research agreement to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments.  The agreement covers research to design and evaluate sd-rxRNA compounds in a human tumor xenograft model.  Positive results may lead to further development of these compounds for treatment of cancer.

  • ACCESSWIRE3 months ago

    RXi Pharmaceuticals Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / RXi Pharmaceuticals Corporation (NASDAQ: RXII ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 ...

  • PR Newswire3 months ago

    RXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights

    MARLBOROUGH, Mass. , Nov. 8, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...

  • PR Newswire4 months ago

    RXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and Conferences

    MARLBOROUGH, Mass. , Nov. 7, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...

  • PR Newswire4 months ago

    RXi Pharmaceuticals to Webcast Third Quarter 2017 Financial Results on Wednesday, November 8, 2017

    MARLBOROUGH, Mass., Nov. 1, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will report its financial results for the third quarter ended September 30, 2017, and provide a business update on Wednesday, November 8, 2017 after the close of the U.S. financial markets. A live audio webcast will begin at 4:30 p.m. ET. RXi Pharmaceuticals Corporation (RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas.

  • PR Newswire4 months ago

    RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum

    MARLBOROUGH, Mass. , Oct. 11, 2017  /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...

  • Marketwired5 months ago

    Streetwise Reports Interviews Executives at Biotech Company with Transformative RNAi Delivery System

    With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. ...

  • Zacks Small Cap Research5 months ago

    RXi Pharmaceuticals’ sd-rxRNA: Better delivery than Amazon!

    NASDAQ:RXII RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a unique player in the RNAi space due to the inherent self-delivery mechanism that efficiently distributes its interference RNA to the cell. ...